Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
← catalyst calendarNCT06298955 · readout ≤ 134 d
Sponsored by Omeros Corporation (industry) · OMER — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25estimated
Sites
5
Countries
Germany, Switzerland, Ukraine +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-19 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Hemoglobinuria
Intervention
- Drug: OMS906 study drug
Primary outcome
what the primary-completion date above is the date OFTo assess overall safety and tolerability of OMS906 administration at 8-week intervals in PNH patients.
measured 104 weeks
Permalink · OMER's whole pipeline · Catalyst calendar · Every registered study · What changed